These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. Lotta LA; Stewart ID; Sharp SJ; Day FR; Burgess S; Luan J; Bowker N; Cai L; Li C; Wittemans LBL; Kerrison ND; Khaw KT; McCarthy MI; O'Rahilly S; Scott RA; Savage DB; Perry JRB; Langenberg C; Wareham NJ JAMA Cardiol; 2018 Oct; 3(10):957-966. PubMed ID: 30326043 [TBL] [Abstract][Full Text] [Related]
6. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118 [TBL] [Abstract][Full Text] [Related]
7. Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. Nelson CP; Lai FY; Nath M; Ye S; Webb TR; Schunkert H; Samani NJ Circ Genom Precis Med; 2019 Jan; 12(1):e002196. PubMed ID: 30645167 [TBL] [Abstract][Full Text] [Related]
8. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315 [TBL] [Abstract][Full Text] [Related]
9. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study. Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118 [TBL] [Abstract][Full Text] [Related]
10. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer. Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819 [TBL] [Abstract][Full Text] [Related]
11. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544 [TBL] [Abstract][Full Text] [Related]
12. Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia. Alsehli AM; Rukh G; Clemensson LE; Ciuculete DM; Tan X; Al-Sabri MH; Williams MJ; Benedict C; Schiöth HB Front Biosci (Landmark Ed); 2021 Dec; 26(12):1453-1463. PubMed ID: 34994160 [TBL] [Abstract][Full Text] [Related]
13. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Schmidt AF; Swerdlow DI; Holmes MV; Patel RS; Fairhurst-Hunter Z; Lyall DM; Hartwig FP; Horta BL; Hyppönen E; Power C; Moldovan M; van Iperen E; Hovingh GK; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Liu T; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott R; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Husemoen LL; Grarup N; Pedersen O; Hansen T; Linneberg A; Simonsen KS; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Kirchner HL; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Smith DJ; Meade T; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Balkau B; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Ridker PM; Chasman DI; Reiner AP; Lange LA; Ritchie MD; Asselbergs FW; Casas JP; Keating BJ; Preiss D; Hingorani AD; ; Sattar N Lancet Diabetes Endocrinol; 2017 Feb; 5(2):97-105. PubMed ID: 27908689 [TBL] [Abstract][Full Text] [Related]
14. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries. Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945 [TBL] [Abstract][Full Text] [Related]
15. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study. Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702 [TBL] [Abstract][Full Text] [Related]
16. Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality. Benn M; Tybjærg-Hansen A; Nordestgaard BG J Am Coll Cardiol; 2019 Jun; 73(24):3102-3114. PubMed ID: 31221259 [TBL] [Abstract][Full Text] [Related]